SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

BioMidwest
Money on the Move: September 15 – 21
The investor trees are dropping their leaves. Here’s who’s benefiting this week in the life sciences industry.
September 21, 2021
 · 
3 min read
 · 
Kate Goodwin
Policy
Biden to Host COVID Summit Calling for “Higher Level of Ambition” to End Pandemic
On the tailcoat of Tuesday’s United Nations General Assembly, President Biden is hosting a virtual COVID-19 summit Wednesday, calling for the end of the pandemic globally.
September 21, 2021
 · 
2 min read
 · 
Kate Goodwin
N. Czarnecki/MediaNews Group/Boston Herald via Get
FDA
Biogen and Samsung Bioepis Heat Up the Lucrative AMD Market with First Biosimilar Approval
Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.
September 20, 2021
 · 
2 min read
 · 
Kate Goodwin
Pictured: Gilead sign in front of tree_JOSH EDELSO
Job Trends
NC Fought Hard for Gilead’s New Site, Adding to Exploding Biotech Presence
Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.
September 17, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: September 8 – 14
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
September 15, 2021
 · 
5 min read
 · 
Kate Goodwin
Deals
Five Life Sciences Companies Ramping up the Fall Flood of IPOs
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
September 13, 2021
 · 
3 min read
 · 
Kate Goodwin
Biotech Bay
Investors Pour $360 Million into Cutting-Edge Biotechs
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
September 9, 2021
 · 
3 min read
 · 
Kate Goodwin
Genetown
Money on the Move: September 1 – 7
Life sciences funding rounds were quieter this week with the Labor Day holiday. Here’s the short list.
September 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Exelixis Mourns Loss of Two Veteran Execs
Exelixis is mourning the loss of two veteran executives—Dr. Gisela M. Schwab, president, Product Development and Medical Affairs and CMO, and Jon Berndt, senior VP of Sales.
September 7, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Eli Lilly Accused of Keeping the Over 40 Crowd Out of Sales Rep Roles
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
September 3, 2021
 · 
3 min read
 · 
Kate Goodwin
Job Trends
Texas Plants its Flag as Next US Biotech Hub
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
September 2, 2021
 · 
3 min read
 · 
Kate Goodwin
Deals
Money on the Move: August 25 – 31
The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.
August 31, 2021
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Cancer Patients Want Warp Speed Given to Oncology Research Next
While the speed of science is both lauded and mistrusted by near-equal parts of the population, the over 22 million Americans with cancer are now saying, “Wait, what about us?”
August 31, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Regeneron and Sanofi Monopoly on Atopic Dermatitis Market May Soon End
Regeneron and Sanofi broke ground with the 2017 approval of the first biologic drug for atopic dermatitis, the most common form of eczema driven by allergic reactions.
August 30, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
A Clinical Stage Biotech Without a CMO? Replimune Makes Surprising Cut
While the biotech market sees a high demand for the chief medical officer role, one Massachusetts oncology player has deemed the role completely unnecessary.
August 26, 2021
 · 
1 min read
 · 
Kate Goodwin
Load More